The next generation of immunotherapies for lung cancers., PMID:40528044
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy., PMID:40507301
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer., PMID:40496850
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies., PMID:40440602
FOXA2 promotes metastatic competence in small cell lung cancer., PMID:40419484
Targeting DLL3: Innovative Strategies for Tumor Treatment., PMID:40284515
Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases., PMID:40280845
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer., PMID:40261494
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review., PMID:40260055
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer., PMID:40177519
Targeting the tumour cell surface in advanced prostate cancer., PMID:40169837
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry., PMID:40165410
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
[New perspectives in the management of small cell bronchial cancer]., PMID:40155069
Current and future perspectives in extensive-stage small-cell lung cancer., PMID:40093978
Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer., PMID:39897044
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer., PMID:39876075
DLL3 draws two antibody-drug conjugate deals., PMID:39806012
New developments in immunotherapy for SCLC., PMID:39762075
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer., PMID:39759138
Assessment of targets of antibody drug conjugates in SCLC., PMID:39748112
Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions., PMID:39703856
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?, PMID:39608345
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study., PMID:39589690
Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC., PMID:39392394
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review., PMID:39326646
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies., PMID:39272956
Immunotherapy for small cell lung cancer: the current state and future trajectories., PMID:39152301
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models., PMID:39143619
Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research., PMID:39090431
Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut., PMID:39061170
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies., PMID:38968122
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients., PMID:38956984
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial., PMID:38950555
FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models., PMID:38940283
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer., PMID:38789515
Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer., PMID:38730739
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy., PMID:38730427
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies., PMID:38645034
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer., PMID:38558120
Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction., PMID:38468968
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate., PMID:38260492
Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel., PMID:38254746
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates., PMID:38001628
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer., PMID:37923915
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer., PMID:37731022
Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy., PMID:37627044
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer., PMID:37468417
For research use only. Not for human or drug use.
